Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Cambridge Cognition Holdings Plc LSE:COG London Ordinary Share GB00B8DV9647 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  15.00 12.4% 136.00 108,301 11:36:31
Bid Price Offer Price High Price Low Price Open Price
135.00 137.00 136.00 122.50 123.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 6.74 -0.65 -1.50 42
Last Trade Time Trade Type Trade Size Trade Price Currency
12:50:00 O 5,500 135.20 GBX

Cambridge Cognition (COG) Latest News

More Cambridge Cognition News
Cambridge Cognition Investors    Cambridge Cognition Takeover Rumours

Cambridge Cognition (COG) Discussions and Chat

Cambridge Cognition Forums and Chat

Date Time Title Posts
15/4/202112:00Cambridge Cognition Holdings (COG)225
09/4/202108:38Dementia - Computerised Neuropsychological Testing179
30/4/201922:22Cambridge Cognition at UK Investor Show1
02/9/201715:05COG with Charts & News63

Add a New Thread

Cambridge Cognition (COG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
11:51:14135.205,5007,436.00O
11:50:01135.002,2293,009.15O
11:43:55136.905,0006,845.00O
11:35:19129.1011,00014,201.00O
11:34:04136.40727991.63O
View all Cambridge Cognition trades in real-time

Cambridge Cognition (COG) Top Chat Posts

DateSubject
15/4/2021
09:20
Cambridge Cognition Daily Update: Cambridge Cognition Holdings Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker COG. The last closing price for Cambridge Cognition was 121p.
Cambridge Cognition Holdings Plc has a 4 week average price of 73p and a 12 week average price of 68p.
The 1 year high share price is 136p while the 1 year low share price is currently 20.50p.
There are currently 31,170,093 shares in issue and the average daily traded volume is 189,179 shares. The market capitalisation of Cambridge Cognition Holdings Plc is £42,391,326.48.
10/4/2021
14:11
40 fathoms: I think there are a number of possible reasons. 1) It is already clear they will blow away the @8.5 million revenue figure they have put out for 2021 and we are only 1/3 of the way through the year. 2) Following on from the point above this would suggest that they will also be meaningfully profitable this year. My working assumption is they will top GBP 1.25 million in PBT this year and depending on how the contracts build that could well top GBP 3.5 next year. Even at 125p per share that puts them on a P/E of 12 x next year and probably single digit for 2023. 3) On 7th April Goldman Sachs did a whole day of talks and panel discussions devoted to digital medicine and with particular focus on how digital clinical trials are now going mainstream. I understand it was very well attended. 4) With the FDA PDUFA date on ADUCANUMAB coming into view (7th June) people maybe positioning for a positive outcome. A positive result will be transformational for COG. It will open a large and near term market for delivering cognitive tests as a triage tool for potential AD patients. Think millions of tests a year being given at (pick your price) US$ 1.00, US$ 2.50, US$ 5 per test. That millions of tests per year will increase to tens of millions in the next decade. It is only COG and Cogstate that are in a position to serve this market. As a reminder Cogstate have done a 10 year deal with Eisai that will pay them a minimum of US$ 45 million over that period. Cogstate are very keen to emphasise that this is a minimum number and they expect very substantial upside. 5) As you suggest someone could well be building a stake, though I would argue with Nigel Wray and one or two other large PIs stakes anyone could well struggle to get to the 75% threshold required under a scheme of arrangement. 6) There is almost no 'traditional" institutional ownership of the stock. Maybe it is starting to gain some attention from the small cap insto crowd.
10/4/2021
08:52
dgwinterbottom: Anyone thought of reasons for the sharp rise in share price this week? It has crossed my mind someone might be building a stake for a possible bid!!
08/4/2021
07:58
40 fathoms: Another very nice contract win. At home, unsupervised, more frequent cognitive testing that is the future for many clinical trials. COG and Cogstate have this space pretty much to themselves.
24/3/2021
10:10
energeticbacker: Investor's Champion comments: The current c£25m valuation (share price 80p - previously 74p), equivalent to only 3.7x historic sales, does not appear to reflect the considerable amount of intellectual property it has accumulated over the past 30 years, supported by thousands of peer-reviewed publications.
15/3/2021
14:22
sharesoc: In case you missed our webinar with Cambridge Cognition the recording and stockopedia report can be found here: hTTps://www.sharesoc.org/seminar/sharesoc-webinar-with-cambridge-cognition-cog-24-february-2021/ To access the recording, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hxxps://www.sharesoc.org/membership/ Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the recording (and recordings/reports on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hxxps://www.sharesoc.org/contact-us/
19/2/2021
08:40
sharesoc: We are hosting a webinar with Cambridge Cognition which may be of interest for current shareholders or potential investors: hTTps://www.sharesoc.org/events/sharesoc-webinar-with-cambridge-cognition-cog-24-february-2021/ Matthew Stork – Chief Executive Officer will be presenting.
13/1/2021
23:39
40 fathoms: Not a chance Cogstate are involved in my view. You go to Cogstate for an excellent commercial/commodity type offering. You go to COG for complex/bespoke research projects exploring leading edge ideas that require analysis and insight. With this large, multi-year, research driven project, COG would be the only commercial group qualified in my view. The reason I suspect COG are involved can be seen from looking at the linkedin page of Biogen's Matt Hobbs, who moved across from COG last year. With no disrespect intended to the excellent scientific team at Cogstate, when it comes to innovation they are not a patch on the COG team (Pam Ventola is a possible exception). For example COG are still researching their voice based products and are probably still at least 24 months away from having a validated product, COG are already in the market and getting paid with their voice project. If we move on to other aspects such as wareables, social cognition, digital phenotyping etc, COG are so far ahead of Cogstate it is not even really open for debate. Where Cogstate are (have been) much stronger than COG is with commercialisation and they continue to do an excellent job at that. However their commercial focus also means they only purse areas where they can get paid at scale rather than one off bespoke projects.
13/1/2021
11:03
40 fathoms: Biogen, Apple to launch virtual study on cognitive decline The research project will be conducted using the Apple Watch and iPhone, and is set to begin during 2021. COG lead the world in this area digital wearables and are the only ones I know off who have previously used apple watches in trials to measure cognition. I reckon there has to be a very good chance that they are involved in this project.
25/11/2020
23:29
40 fathoms: I am assuming you are talking about AD in a healthcare context ? I don't think it will have any impact what so ever as the article itself says it is seen as complementary to cognitive testing not a replacement. Firstly as a triage tool and from a price and ease of administration viewpoint you will never beat a digital test costing a few US$. Secondly, even if you can detect beta amyloid in the blood you will still need to monitor and assess the cognitive impact, which will very greatly amongst patients and that can only be done by cognitive testing. Finally, at present this is a tiny part of COGs business and even if this was (and it wont) to close the triage AD market to COG there a large number of other health care applications for their various tests. If it has any negative impact it would be more for a company like IXICO, if they were ever to move in to the healthcare setting.
26/10/2020
06:15
40 fathoms: Today Eisai just paid a minimum of US$ 45 million (US$ 15 million upfront) for a 10 year licence with royalties to use Cogstate’s Cognigram product in healthcare. Given our significant advantages over Cognigram and the distinct lack of validated competition in this space, there is no reason why there is not a similar sort of deal somewhere out there for us. Imagine what our share price would do if we had announced a similar deal today. On a slightly different note I think it is interesting that Eisai did this deal prior to the November 6th FDA advisory committee steer on Aducanumab, given they are the junior partner to Biogen for this drug.
Cambridge Cognition share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
COG
Cambridge ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210415 12:14:33